bullish
China Population Policies Impact on Healthcare Companies Series - Part 3
984 Views05 Jan 2024 10:32
SUMMARY
- Starting from November 1st 2023, Guangxi Zhuang Autonomous Region will include some therapeutic assisted reproductive medical services in the payment scope of basic medical insurance and work-related injury insurance funds.
- Livzon’s 23Q3 performance was below expectations, which is related to China’s anti-corruption campaign started from 23H2. Considering the Chairman's proposal to repurchase shares, we should be more patient with Livzon.
- BGI is still digesting the impact of COVID revenue, and would experience a performance low point in 2023.However, BGI belongs to the direction of national key science and technology projects.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- China Population Policies Impact on Healthcare Companies Series – Part 419 Apr 2024
- China Population Policies Impact on Healthcare Companies Series - Part 305 Jan 2024
- WuXi XDC Cayman (2268.HK) - Would It Be An "Oasis in the Desert"?03 Jan 2024
- China Population Policies Impact on Healthcare Companies Series – Part 203 Oct 2023
- China Population Policies Impact on Healthcare Companies Series - Part 118 Jul 2023
x